RAPID COMMUNICATION

Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke

Pascal Hindelang,1 Andreas Scharinger,1 Patricia Golombek,1 Miriam Laible,2 Sandra Tamosaité,2 Stephan G. Walch,1 and Dirk W. Lachenmeier1,*

Abstract

Introduction: Recent research claimed that CBD in commercial electronic cigarette (e-cigarette) liquids can be converted into psychotropic amounts of Δ9-THC. This study aims to validate this claim using a realistic e-cigarette setup. In addition, this study also investigates if such a conversion may occur during smoking of CBD-rich cannabis joints.

Materials and Methods: Two different CBD liquids were vaporized using two different e-cigarette models, one of which was operated at extreme energy settings (0.2 Ω and 200 W). The smoke of six CBD joints was collected using a rotary smoking machine according to ISO 4387:2019. Analyses were conducted using nuclear magnetic resonance spectrometry as well as liquid chromatography tandem mass spectrometry.

Results: For the condensed e-cigarette liquids, no increase in THC concentration could be observed. For the CBD joints, no THC formation was provable. The recovered THC concentrations were ranging between 1% and 48% (0.034 and 0.73 mg) of the THC amount initially contained in the joints before smoking.

Conclusions: Using realistic conditions of consumer exposure, relevant conversion of CBD to THC appears to not be occurring. The health risk of CBD liquids for e-cigarettes, as well as low-THC cannabis intended for smoking, can be assessed by concentrations in the source material without the need to consider significant changes in psychotropic compounds during use by consumers.

Keywords: cannabidiol; tetrahydrocannabinol; hemp; Cannabis sativa; cannabis smoking; electronic cigarettes; risk assessment

Introduction

E-liquids containing the nonpsychotropic CBD as well as CBD-rich but Δ9-THC-poor varieties of cannabis are offered for consumption, but depending on the jurisdiction are not allowed to exceed certain thresholds of THC.1–3 Unlike international standards for evaluating tobacco cigarettes, which typically apply routine analytical cigarette smoking machines, the regulatory acceptability of cannabis preparations for vaping or smoking is currently determined by analyzing the e-liquid or low-THC cannabis in the preparation as it is sold. Recent research has questioned this...
practice, as it has been claimed that CBD can be converted to THC by thermic vaporization of commercial e-liquids in commercial electronic cigarettes (e-cigarettes) in significant amounts (42–70% of decomposition products).4

The authors suggested to reconsider the viewpoint that CBD in e-cigarette liquids does not appear to have any psychotropic effect or any harmful effect on human health. However, a study by Kintz measured CBD concentrations in blood samples from consumers of CBD-containing e-liquids without Δ9-THC being detected in blood samples.5 Regarding smoking of low-THC cannabis, Gelmi et al observed blood THC concentrations at levels reported to cause impairment symptoms, but were unable to confirm such effects in a randomized double-blind placebo-controlled two-way crossover study.6 In a similar clinical trial, Arkell et al reported considerably lower blood THC concentrations and excluded clinically important impairment.7

To further investigate whether the conversion of CBD to Δ9-THC occurs in CBD e-cigarettes and low-THC cannabis smoke, and if future risk assessment would need to consider this effect, this study is the first to measure Δ9-THC concentrations in condensates from vaporized e-liquids and low-THC cannabis smoked using a routine analytical cigarette smoking machines.

Materials and Methods

CBD e-liquids and low-THC cannabis were taken from samples from retail sale in Germany submitted to our institutes for regulatory control purposes.

The e-liquids contained CBD in concentrations of 55 g/L CBD and 100 g/L CBD in a propylene glycol/glycerol matrix. The liquids were loaded into an e-cigarette. The mouthpiece (“Drip Tip”) of the e-cigarette was connected to a syringe (volume 60 mL) through a flexible PVC tube. This study used two commercial e-cigarette devices. The first one (device 1) was eGo AIO All-in-One Style, 5–20 W, 1700 mAh, Vaporizer type BF SS316, 0.5 Ω (Shenzhen Joyetech Co., Ltd., Shenzhen, China).

As it became quickly evident that no THC had been formed with this device, a second device (device 2) allowing higher energy setting was purchased: Geekvape Ageis Legend Kit with additional vaporizer coils and Geekvape Z Sub-Ω Tank (Geekvape Z Series coils; Geekvape, Shenzen, China). The settings for the e-cigarette coils were set to a maximum of 0.2 Ω and 200 W to allow a maximum amount of heat for the vaporization process of the e-liquids. Before vaporization, each e-liquid was loaded into an individual refillable e-cigarette tank with a new vaporizer coil. The airflow control of the e-cigarette was adjusted to allow maximum air intake.

The vaporization was conducted stepwise until the syringe was filled with vapor to the 60 mL mark. The syringe was then removed from the PVC tube, sealed with multiple layers of parafilm, and placed on a laboratory bench until the vapor was condensed completely.

The condensate was collected by inserting 2 mL of deuterated methanol (MeOD) into the syringe. From the condensate methanol mixture, 600 μL were transferred to a nuclear magnetic resonance (NMR) tube for the quantification of Δ9-THC and CBD in a Bruker 400 MHz Ultrasound NMR spectrometer (Bruker, Rheinstetten, Germany). The NMR method was previously described in detail.8 As a reference sample, the same amount of unvaporized e-liquid was dissolved in 2 mL of MeOD and also prepared for measurement.

From each remaining sample solution, which has been obtained from vaporizing the liquids at 0.2 Ω and 200 W, dilutions were prepared for the quantification of Δ9-THC and CBD using a previously described liquid chromatography tandem mass spectrometry (LC-MS/MS) method9 with the following modifications to improve separation of cannabinoids: separation column Raptor, ARC-18, 2.7 μm, 150×2.1 mm (Shimadzu Deutschland GmbH, Duisburg, Germany). The separation was isocratic with 20% water and 80% methanol, containing 0.1% of formic acid.

For low-THC cannabis, joints were prepared using 1 g of cannabis per joint. Using a routine analytical cigarette smoking machine according to ISO 3308:2012 (RM 20 H; Borgwaldt, Hamburg, Germany) the joints were smoked without prior conditioning and the combined smoke of five joints adsorbed on a filter paper (92 mm). The filter paper was then extracted with methanol and the extract was analyzed using LC-MS/MS.9

Institutional review board approval was not required because this study was purely experimental and did not involve any human participants.

Results

Table 1 presents the recovery of Δ9-THC in the condensates of vaporized liquids compared with the Δ9-THC concentrations measured in pure CBD liquids. The results
indicate that for none of the settings investigated for the e-cigarette, Δ⁹-THC could be detected in the obtained condensates by using ¹H NMR spectroscopy. LC-MS/MS measurements have confirmed that an increase in Δ⁹-THC concentration at the highest energy setting did not occur.

The results of Δ⁹-THC recovered during the ISO smoking regime are shown in Table 2. About 1–48% of Δ⁹-THC (0.034–0.73 mg) initially contained in the cannabis plant material was found.

Discussion

¹H NMR spectroscopy of Δ⁹-THC in condensates indicates that an overall formation of Δ⁹-THC does not occur in commercial CBD liquids. These findings are consistent with previous findings from Kintz.⁵ Further analytical measurements using more sensitive LC-MS/MS have confirmed that no formation of Δ⁹-THC after heating occurred. Note that a decrease in CBD concentrations in condensates has not been observed in any measured sample using NMR, therefore also confirming that thermic conversion of CBD to Δ⁹-THC did not occur.

Cze´gény et al reported a high conversion rate of CBD to Δ⁹-THC (corresponding to 0.5–1 mg/mL e-liquid).⁴ However, the study was conducted with pure CBD in methanol solution instead of an e-cigarette matrix (e.g., propylene glycol and glycerol) and without a realistic e-cigarette setup, since the measurements were purely conducted using a pyrolysis gas chromatography system (i.e., without any e-cigarette setup before analysis). Therefore, the authors do not believe that the results of Cze´gény et al⁴ have any practical value and do not allow one to make judgment about e-cigarettes. The authors also believe that the interpretation of Cze´gény et al⁴ to reconsider psychotropic effects of CBD liquids is not founded in the data of the study, and clearly must be rebutted by the data from this study.

Similarly, our results show that by smoking of low-THC cannabis, only a fraction of THC is recovered in the smoke. Although cannabis contains other potential THC precursors besides CBD, the formation of THC from CBD or other precursors can be excluded in this case as well. Even the case of the highest THC concentration recovered in our samples (0.73 mg/5 joints) would be below psychotropic levels.¹⁰ This is in line with other data showing that inhalation of vaporized and combusted CBD-dominant cannabis preparations did not result in any detectable cognitive impairment of study participants regarding driving behavior.⁶,⁷

Concerning consumer safety, it is not recommended to consume CBD liquids or e-liquids in general with the respective power outputs tested in this investigation (possibly in the false belief to produce psychotropic

### Table 1. Relative Increase in Δ⁹-Tetrahydrocannabinol Concentrations in Recovered Condensates After Vaporization of E-Liquids

| Power settings/device type | Liquid A (3 mg/L Δ⁹-THC<sub>a</sub>) | Liquid B (9 mg/L Δ⁹-THC<sub>b</sub>) |
|----------------------------|--------------------------------------|--------------------------------------|
| 0.5 Ω; 23 W/device 1       | No increase in Δ⁹-THC detected<sup>b</sup> | No increase in Δ⁹-THC detected<sup>b</sup> |
| 0.6 Ω; 28 W/device 1       | No increase in Δ⁹-THC detected<sup>b</sup> | No increase in Δ⁹-THC detected<sup>b</sup> |
| 0.2 Ω; 80 W/device 2       | No increase in Δ⁹-THC detected<sup>b</sup> | No increase in Δ⁹-THC detected<sup>b</sup> |
| 0.2 Ω; 120 W/device 2      | No increase in Δ⁹-THC detected<sup>b</sup> | No increase in Δ⁹-THC detected<sup>b</sup> |
| 0.2 Ω; 150 W/device 2      | No increase in Δ⁹-THC detected<sup>b</sup> | No increase in Δ⁹-THC detected<sup>b</sup> |
| 0.2 Ω; 200 W/device 2      | No increase in Δ⁹-THC detected<sup>b,c</sup> | No increase in Δ⁹-THC detected<sup>b,c</sup> |

<sup>a</sup>Original liquids measured using LC-MS/MS.
<sup>b</sup>Measurements were conducted using ¹H NMR spectroscopy.
<sup>c</sup>Condensates obtained at the highest power setting were additionally measured using LC-MS/MS.

### Table 2. Recovery of Δ⁹-THC After Smoking of Low THC Cannabis

| Sample | Δ⁹-THC before smoking (per 5 joints containing 1 g of cannabis) | Δ⁹-THC recovered during ISO 4387:2019 smoking regime |
|--------|---------------------------------------------------------------|-----------------------------------------------------|
| 1<sup>a</sup> | 2.02 mg | 0.200 mg (10%) |
| 2<sup>a</sup> | 1.26 mg | 0.070 mg (6%) |
| 3<sup>b</sup> | 3.19 mg | 0.034 mg (1%) |
| 4<sup>b</sup> | 3.30 mg | 0.130 mg (4%) |
| 5<sup>b</sup> | 2.83 mg | 0.240 mg (8%) |
| 6<sup>b</sup> | 1.52 mg | 0.730 mg (48%) |

<sup>a</sup>Smoking regime strictly according to the ISO standard conditions (as for tobacco cigarettes), that is, one puff every 60 sec with a puff duration of 2 sec and 35 mL puff volume.
<sup>b</sup>After the joints ran out between the puffs and had to be relit manually, the puff parameters for the other four samples were changed as follows: puff frequency 50 sec, puff duration 5 sec, and puff volume 55 mL. Smoking then worked much better.
levels of THC). For example, harmful substances such as benzene can be formed from propylene glycol and glycerol, especially in high-power settings. Note that the e-cigarette itself heated up, so concerns regarding the safety and reliability of the device may arise when operated in the settings used.

Furthermore, the high temperature of the vaporized liquid and the heating of the mouthpiece during the vaporization procedure might also cause severe injuries to lung tissue and burns to the mouth and oral epithelium, respectively. It should also be noted that upon inhalation at the highest temperature settings, the condensate and the remaining CBD liquid had a strongly unpleasant ammonia smell, which would make the consumption of CBD liquids with the respective settings impossible. This was observed in both liquids and may result from matrix and aroma compounds or non-inert components of the device (such as sealants and the vaporizer coil), which could have been broken down or disintegrated by high temperatures resulting from high power output.

Consumers should also be warned against vaping other unregulated compounds such as synthetic or semisynthetic cannabinoids. For example, in a very similar experimental setup to this study, Munger et al were recently able to show that vaping of \( \Delta^8 \)-THC may form the toxic compound ketene that had been associated as underlying mechanism for the cause of e-cigarette, or vaping, product use associated lung injury (EVALI) as it may also be formed from vitamin E acetate, which had been contained in some CBD e-liquids. The consideration that EVALI was not caused by cannabinoids but other compounds in the e-cigarette liquids was recently validated by a risk assessment of inhaled CBD and THC, which found that the intake would be typically below thresholds of toxicity. Nevertheless, it was also remarked that the available data for risk assessment of CBD is rather limited. Caution is also advised because CBD products may potentially lead to positive urine drug tests due to significant contamination with THC and other cannabinoids.

Conclusions
In general, the vaporization or burning of natural materials such as cannabis extracts or cannabis plant materials is a multifactorial process that is characterized by various steps from acidic forms of cannabinoids to neutral cannabinoids and further oxidation products. Our results show that CBD-rich cannabis under vaporization or burning conditions does not form \( \Delta^2 \)-THC concentrations. The authors, therefore, believe that the risk of consumer products based on low-THC cannabis or hemp can be further assessed for regulatory purposes by direct analysis of the products as such.

Acknowledgments
The authors warmly thank the teams at the cannabis, NMR, tobacco, and LC/MS laboratories for excellent technical assistance.

Authors’ Contributions
The authors affirm that they have each met the criteria for authorship as defined by the International Committee of Medical Journal Editors.

Author Disclosure Statement
No competing financial interests exist.

Funding Information
No funding was received for this article.

References
1. Golombek P, Müller M, Barthlott I, et al. Conversion of cannabidiol (CBD) into psychotropic cannabinoids including tetrahydrocannabinol (THC). A controversy in the scientific literature. Toxics 2020;8(2):41; doi: 10.3390/toxics8020041
2. Tallon MJ. Cannabis sativa L. and its extracts. Regulation of cannabidiol in the European Union and United Kingdom. J Dietary Suppl 2020;17(5): 503–516; doi: 10.1080/19390211.2020.1795044
3. Dunn K, Taylor A, Tursus S. A review of cannabidiol-containing electronic liquids-Current regulations and labelling accuracy. Drug Test Anal 2021;13(8):1490–1498; doi: 10.1002/dta.3102
4. Czégyén Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11(1):8951; doi: 10.1038/s41598-021-88389-z
5. Kintz P. Vaping pure cannabidiol e-cigarettes does not produce detectable amount of \( \Delta^9 \)-THC in human blood. J Anal Toxicol 2021;44(9):e1–e2; doi: 10.1093/jat/bkaa008
6. Gelmi TJ, Weinmann W, Pfaffli M. Impact of smoking cannabidiol (CBD)-rich marijuana on driving ability. Forensic Sci Res 2021;6(3):195–207; doi: 10.1080/20961790.2021.1946924
7. Arkell TR, Vinkelboch F, Kevin RC, et al. Effect of cannabidiol and \( \Delta^9 \)-tetrahydrocannabinol on driving performance. A randomized clinical trial. JAMA 2020;324(21):2177–2186; doi: 10.1001/jama.2020.21218
8. Barthlott I, Scharinger A, Golombek P, et al. A quantitative 1H NMR method for screening cannabinoids in CBD oils. Toxics 2021;9(6):136; doi: 10.3390/toxics9060136
9. Lachenmeier DW, Habel S, Fischer B, et al. Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? F1000 Res 2021;8:1394; doi: 10.12688/f1000research.19931.4
10. Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep 2015;5:8126; doi: 10.1038/srep08126
11. Pankow JF, Kim K, McWhirter KJ, et al. Benzene formation in electronic cigarettes. PLoS One 2017;12(3):e0173055; doi: 10.1371/journal.pone.0173055

12. Munger KR, Jensen RP, Strongin RM. Vaping cannabinoid acetates leads to ketene formation. Chem Res Toxicol 2022;35(7):1202–1205; doi: 10.1021/acs.chemrestox.2c00170

13. Duffy B, Li L, Lu S, et al. Analysis of cannabinoid-containing fluids in illicit vaping cartridges recovered from pulmonary injury patients: Identification of vitamin E acetate as a major diluent. Toxics 2020;8(1):8; doi: 10.3390/toxics8010008

14. Hindelang P, Scharinger A, Richling E, et al. Using the BMD approach to derive acceptable daily intakes of cannabidiol (CBD) and tetrahydrocannabinol (THC) relevant to electronic cigarette liquids. Front Biosci (Landmark Ed) 2022;27(8):228; doi: 10.31083/j.fbi2708228

15. Lachenmeier DW, Diel P. A Warning against the negligent use of cannabidiol in professional and amateur athletes. Sports 2019;7(12):251; doi: 10.3390/sports7120251

**Cite this article as:** Hindelang P, Scharinger A, Golombek P, Laible M, Tamosaitė S, Walch SG, Lachenmeier DW (2022) Absence of relevant thermal conversion of cannabidiol to tetrahydrocannabinol in e-cigarette vapor and low-tetrahydrocannabinol cannabis smoke, Cannabis and Cannabinoid Research 7:5, 616–620, DOI: 10.1089/can.2022.0163.

**Abbreviations Used**

| Abbreviation | Description |
|--------------|-------------|
| CBD          | cannabidiol |
| e-cigarette  | electronic cigarette |
| EVALI        | e-cigarette, or vaping, product use associated lung injury |
| LC-MS/MS     | liquid chromatography tandem mass spectrometry |
| MeOD         | deuterated methanol |
| NMR          | nuclear magnetic resonance |
| THC          | tetrahydrocannabinol |